Shell Asset Management Co. Makes New $102,000 Investment in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Shell Asset Management Co. bought a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Rating) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,119 shares of the company’s stock, valued at approximately $102,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in PROCEPT BioRobotics by 18.2% during the 1st quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company’s stock worth $188,000 after purchasing an additional 825 shares during the last quarter. Amalgamated Bank acquired a new position in shares of PROCEPT BioRobotics during the 1st quarter valued at about $39,000. US Bancorp DE acquired a new position in shares of PROCEPT BioRobotics during the 2nd quarter valued at about $37,000. Charles Schwab Investment Management Inc. boosted its position in shares of PROCEPT BioRobotics by 2.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 51,391 shares of the company’s stock valued at $1,799,000 after acquiring an additional 1,206 shares during the last quarter. Finally, UBS Group AG boosted its position in shares of PROCEPT BioRobotics by 9.8% during the 1st quarter. UBS Group AG now owns 20,506 shares of the company’s stock valued at $718,000 after acquiring an additional 1,837 shares during the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.

PROCEPT BioRobotics Trading Up 1.6 %

NASDAQ PRCT opened at $44.88 on Friday. The firm’s 50-day moving average is $42.42 and its two-hundred day moving average is $39.59. PROCEPT BioRobotics Co. has a 12 month low of $15.38 and a 12 month high of $52.40. The company has a debt-to-equity ratio of 0.24, a current ratio of 10.56 and a quick ratio of 9.74. The stock has a market capitalization of $2.01 billion, a P/E ratio of -25.65 and a beta of 1.00.

Analyst Ratings Changes

Several research analysts have recently weighed in on PRCT shares. BTIG Research started coverage on shares of PROCEPT BioRobotics in a research report on Monday, October 31st. They set a “neutral” rating on the stock. Truist Financial boosted their price target on shares of PROCEPT BioRobotics from $56.00 to $58.00 in a research report on Monday, November 14th. The Goldman Sachs Group boosted their price target on shares of PROCEPT BioRobotics from $39.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, November 4th. KeyCorp boosted their price target on shares of PROCEPT BioRobotics from $47.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, November 4th. Finally, Wells Fargo & Company initiated coverage on shares of PROCEPT BioRobotics in a research report on Friday, September 2nd. They issued an “overweight” rating and a $49.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.50.

PROCEPT BioRobotics Company Profile

(Get Rating)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Further Reading

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Rating).

Institutional Ownership by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.